<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128110</url>
  </required_header>
  <id_info>
    <org_study_id>7717</org_study_id>
    <nct_id>NCT05128110</nct_id>
  </id_info>
  <brief_title>Study of Hemostasis During the Atrial Fibrillation Ablation Procedure</brief_title>
  <acronym>EHPAFAVE</acronym>
  <official_title>Study of Hemostasis During the Atrial Fibrillation Ablation Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the high thrombotic risk during the atrial fibrillation procedure, new guidelines have&#xD;
      been proposed to maintain direct oral anticoagulant therapy during the perioperative period.&#xD;
      This resulted in a significant change in the activated clotting time (ACT) at the beginning&#xD;
      of the procedure, making it difficult to assess the level of heparinization during the&#xD;
      procedure. The main objective of this study was to evaluate the correlation between&#xD;
      laboratory hemostatic parameters, ACT and the dose of unfractionated heparin received. The&#xD;
      secondary objective of this study was to correlate these results with hemorrhagic or&#xD;
      thrombotic complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study of hemorrhagic and thrombotic complications and correlation with the various laboratory tests</measure>
    <time_frame>Files analysed retrospectively from January 01, 2019 to December 31, 2019 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hemostasis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patient with an atrial fibrillation, perated for an atrial fibrillation procedure in&#xD;
        the University hospital of Strasbourg and without interruption of the direct oral&#xD;
        anticoagulant&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years-old&#xD;
&#xD;
          -  with an atrial fibrillation&#xD;
&#xD;
          -  Operated for an atrial fibrillation procedure in the University hospital of Strasbourg&#xD;
&#xD;
          -  Without interruption of the direct oral anticoagulant&#xD;
&#xD;
          -  For whom extended biological assessment has been made in routine practice&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refused the use of their data for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Charles-Ambroise TACQUARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles-Ambroise TACQUARD, MD</last_name>
    <phone>33 3 69 55 16 08</phone>
    <email>charlesambroise.tacquard@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles-Ambroise TACQUARD, MD</last_name>
      <phone>33 3.69 55 16 08</phone>
      <email>charlesambroise.tacquard@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Charles-Ambroise TACQUARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence JESEL, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annick STEIB, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lelia GRUNEBAUM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier DELABRANCHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David MILLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Ablation</keyword>
  <keyword>ACT</keyword>
  <keyword>Heparin</keyword>
  <keyword>Direct oral anticoagulant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

